Pollinex Quattro: An innovative four injections immunotherapy In allergic rhinitis

References

• Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al, World Health Organization, GA(2)LEN, AllerGen. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63:Suppl 86 8 - 160; http://dx.doi.org/10.1111/j.1398-9995.2007.01620.x; PMID: 18331513
   PubMed Web of Science ®Google Scholar
• Patel P, Salapatek AM. Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine. Expert Rev Vaccines 2006; 5:617 - 29; http://dx.doi.org/10.1586/14760584.5.5.617; PMID: 17181436
   PubMed Web of Science ®Google Scholar
• Corren J. The connection between allergic rhinitis and bronchial asthma. Curr Opin Pulm Med 2007; 13:13 - 8; http://dx.doi.org/10.1097/MCP.0b013e328010d0db; PMID: 17133119
   PubMed Web of Science ®Google Scholar
• van Cauwenberge P, Bachert C, Passalacqua G, Bousquet J, Canonica GW, Durham SR, et al, European Academy of Allergology and Clinical Immunology. Consensus statement on the treatment of allergic rhinitis. Allergy 2000; 55:116 - 34; http://dx.doi.org/10.1034/j.1398-9995.2000.00526.x; PMID: 10726726
   PubMed Web of Science ®Google Scholar
• Wheeler AW, Woroniecki SR. Allergy vaccines--new approaches to an old concept. Expert Opin Biol Ther 2004; 4:1473 - 81; http://dx.doi.org/10.1517/14712598.4.9.1473; PMID: 15335314
   PubMed Web of Science ®Google Scholar
• Rolland JM, Gardner LM, O’Hehir RE. Allergen-related approaches to immunotherapy. Pharmacol Ther 2009; 121:273 - 84; http://dx.doi.org/10.1016/j.pharmthera.2008.11.007; PMID: 19111571
   PubMed Web of Science ®Google Scholar
• Gawchik SM, Saccar CL. Pollinex Quattro Tree: allergy vaccine. Expert Opin Biol Ther 2009; 9:377 - 82; http://dx.doi.org/10.1517/14712590802699596; PMID: 19216626
   PubMed Web of Science ®Google Scholar
• Rose MA. Das Adjuvans Monophosphoryl-Lipid A (MPL) - Vom Endotoxin zur effizienten SIT. Derm 2/2012.
   Google Scholar
• Pfaar O, Klimek L. Einsatz von Adjuvanzien bei der allergen-spezifischen Immuntherapie. Allergo J 2011; 20:60 - 70
   Google Scholar
• Garçon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007; 6:723 - 39; http://dx.doi.org/10.1586/14760584.6.5.723; PMID: 17931153
   PubMed Web of Science ®Google Scholar
• Brehler R, Kleine-Tebbe J. Extraktvarianten und Adjuvanzien zur spezifischen Immuntherapie. Allergo J 2008; 17:224 - 7
   Google Scholar
• Wheeler AW, Moran DM, Robins BE, Driscoll A. l-Tyrosine as an immunological adjuvant. Int Arch Allergy Appl Immunol 1982; 69:113 - 9; http://dx.doi.org/10.1159/000233157; PMID: 7107028
   PubMedGoogle Scholar
• Baldrick P, Richardson D, Wheeler AW. Review of L-tyrosine confirming its safe human use as an adjuvant. J Appl Toxicol 2002; 22:333 - 44; http://dx.doi.org/10.1002/jat.869; PMID: 12355563
   PubMed Web of Science ®Google Scholar
• Baldridge JR, McGowan P, Evans JT, Cluff C, Mossman S, Johnson D, et al. Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin Biol Ther 2004; 4:1129 - 38; http://dx.doi.org/10.1517/14712598.4.7.1129; PMID: 15268679
   PubMed Web of Science ®Google Scholar
• Akira S. Innate immunity and adjuvants. Philos Trans R Soc Lond B Biol Sci 2011; 366:2748 - 55; http://dx.doi.org/10.1098/rstb.2011.0106; PMID: 21893536
   PubMed Web of Science ®Google Scholar
• McCormack PL, Wagstaff AJ. Ultra-short-course seasonal allergy vaccine (Pollinex Quattro). Drugs 2006; 66:931 - 8; http://dx.doi.org/10.2165/00003495-200666070-00004; PMID: 16740007
   PubMed Web of Science ®Google Scholar
• Drachenberg KJ, Wheeler AW, Stuebner P, Horak F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001; 56:498 - 505; http://dx.doi.org/10.1034/j.1398-9995.2001.056006498.x; PMID: 11421893
   PubMed Web of Science ®Google Scholar
• Drachenberg KJ, Heinzkill M, Urban E. Kurzzeit-Immuntherapie mit Baumpollen-Allergoiden und dem Adjuvans Monophosphoryl Lipid-A. Allergologie 2002; 25:466 - 74
   Google Scholar
• Mothes N, Heinzkill M, Drachenberg KJ, Sperr WR, Krauth MT, Majlesi Y, et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 2003; 33:1198 - 208; http://dx.doi.org/10.1046/j.1365-2222.2003.01699.x; PMID: 12956739
   PubMed Web of Science ®Google Scholar
• Rosewich M, Schulze J, Eickmeier O, Telles T, Rose MA, Schubert R, et al. Tolerance induction after specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A in children. Clin Exp Immunol 2010; 160:403 - 10; http://dx.doi.org/10.1111/j.1365-2249.2010.04106.x; PMID: 20345983
   PubMed Web of Science ®Google Scholar
• Drachenberg KJ, Heinzkill M, Urban E, Woroniecki SR. Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MPL) for children and adolescents. Allergol Immunopathol (Madr) 2003; 31:270 - 7; http://dx.doi.org/10.1016/S0301-0546(03)79195-2; PMID: 14572416
   PubMedGoogle Scholar
• Martin M, Michalek SM, Katz J. Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A. Infect Immun 2003; 71:2498 - 507; http://dx.doi.org/10.1128/IAI.71.5.2498-2507.2003; PMID: 12704121
   PubMed Web of Science ®Google Scholar
• Puggioni F, Durham SR, Francis JN. Monophosphoryl lipid A (MPL) promotes allergen-induced immune deviation in favour of Th1 responses. Allergy 2005; 60:678 - 84; http://dx.doi.org/10.1111/j.1398-9995.2005.00762.x; PMID: 15813815
   PubMed Web of Science ®Google Scholar
• Stuck BA, Schneide-Gene S, Schäfer D, et al. Short-term preseasonal immunotherapy with birch pollen allergoid plus monophosphoryllipid A (MPL). Allergy Clin Immunol Int 2004; 16:60 - 4; http://dx.doi.org/10.1027/0838-1925.16.2.60
   Google Scholar
• Roever AC, Reimann S, Zuberbier T, Worm M. Immunophenotypic characterization of peripheral B cells. During short-term immunotherapy with tree pollen allergoid and the immunoadjuvant monophosphoryl lipid A. J Invest Allergol. Clin Immunol 2002; 12:227 - 223
   Web of Science ®Google Scholar
• DuBuske LM, Frew AJ, Horak F, Keith PK, Corrigan CJ, Aberer W, et al. Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen. Allergy Asthma Proc 2011; 32:239 - 47; http://dx.doi.org/10.2500/aap.2011.32.3453; PMID: 21535913
   PubMed Web of Science ®Google Scholar
• Drachenberg KJ, Proell S, Urban E, Woroniecki SR. Short-term immunotherapy using an allergy vaccine adjuvanted with monophosphoryl lipid A: a post-marketing surveillance study. Int Rev Allergol Clin Immunol 2002; 8:219 - 23
   Google Scholar
• Zielen S, Metz D, Sommer E, Scherf HP. Short-term immunotherapy with allergoids and the adjuvant monophosphoryl lipid A. Allergologie 2007; 30:Suppl 1 S1 - 8
   Web of Science ®Google Scholar
• Rosewich M, Schulze J, Fischer von Weikersthal-Drachenberg KJ, Zielen S. Ultra-short course immunotherapy in children and adolescents during a 3-yrs post-marketing surveillance study. Pediatr Allergy Immunol 2010; 21:e185 - 9; http://dx.doi.org/10.1111/j.1399-3038.2009.00953.x; PMID: 20003062
   PubMed Web of Science ®Google Scholar
• Frew AJ, DuBuske L, Keith PK, Corrigan CJ, Aberer W, Fischer von Weikersthal-Drachenberg KJ. Assessment of specific immunotherapy efficacy using a novel placebo score-based method. Ann Allergy Asthma Immunol 2012; 109:342 - 7, e1; http://dx.doi.org/10.1016/j.anai.2012.08.013; PMID: 23062390
   PubMedGoogle Scholar
• Rabe U, Fiedler G, Piller M. 4-Jahresdaten zur Verbesserung der Lebensqualität bei Patienten mit Baumpollenallergie nach subkutaner Kurzzeit-Immuntherapie (SCIT) mit Allergoiden und dem Adjuvans Monophosphoryl-Lipid A (MPL®); 6. Deutscher Allergiekongress Wiesbaden 2011, Poster-Nr. 11.
   Google Scholar
• Rabe U, Fiedler G, Piller M. 4-Jahresdaten zur Verbesserung der Lebensqualität bei Patienten mit Graspollenallergie nach subkutaner Kurzzeit-Immuntherapie (SCIT) mit Allergoiden und dem Adjuvans Monophosphoryl-Lipid A (MPL®); 6. Deutscher Allergiekongress Wiesbaden 2011, Poster-Nr. 12.
   Google Scholar
• Stollewerk D, Reiber R, Greving J, et al. Comparison of efficacy of conventional subcutaneous immunotherapy (SCIT) and ultra-short SCIT containing Monophosphoryl Lipid A (MPL): results of a multicentre observational study after two years of treatment. 29th Congress of the European Academy of Allergy and Clinical Immunology London, 2010; Poster #670.
   Google Scholar
• Claes C, Mittendorf T, Graf von der Schulenburg JM. Gesundheitsökonomische Modellierung der allergenspezifischen Immuntherapie bei saisonaler allergischer Rhinitis aus Sicht der Kostenträger. Allergo J 2009; 18:60 - 70
   Google Scholar
• Verstraeten T, Descamps D, David MP, Zahaf T, Hardt K, Izurieta P, et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 2008; 26:6630 - 8; http://dx.doi.org/10.1016/j.vaccine.2008.09.049; PMID: 18845199
   PubMed Web of Science ®Google Scholar
• Pollinex Quattro. Summary of Product Characteristics. Bencard Allergie GmbH. June 2011.
   Google Scholar
• Durham SR, Walker SM, Varga EM, Jacobson MR, O’Brien F, Noble W, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341:468 - 75; http://dx.doi.org/10.1056/NEJM199908123410702; PMID: 10441602
   PubMed Web of Science ®Google Scholar
• Pfaar O, Barth C, Jaschke C, Hörmann K, Klimek L. Sublingual allergen-specific immunotherapy adjuvanted with monophosphoryl lipid A: a phase I/IIa study. Int Arch Allergy Immunol 2011; 154:336 - 44; http://dx.doi.org/10.1159/000321826; PMID: 20975285
   PubMed Web of Science ®Google Scholar
• Baldrick P, Richardson D, Wheeler AW. Safety evaluation of a glutaraldehyde modified tyrosine adsorbed housedust mite extract containing monophosphoryl lipid A (MPL) adjuvant: a new allergy vaccine for dust mite allergy. Vaccine 2001; 20:737 - 43; http://dx.doi.org/10.1016/S0264-410X(01)00413-3; PMID: 11738737
   PubMed Web of Science ®Google Scholar